Price to earnings forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC
This page from TradingView provides financial information specifically focusing on the "Price to earnings forward" metric for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It indicates the company's ticker symbol, NASDAQ listing, and highlights specific financial data points related to its forward P/E ratio.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to three new non-executive employees, consisting of 44,400 non-qualified stock options and 7,200 restricted stock units. These grants were approved by ORIC's Compensation Committee and serve as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). The grants have specific vesting schedules and are part of the company's 2022 Inducement Equity Incentive Plan, aimed at retaining talent to further its mission of developing oncology treatments.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to three new non-executive employees, consisting of 44,400 non-qualified stock options and 7,200 restricted stock units. These grants, approved by ORIC's Compensation Committee, were made under the 2022 Inducement Equity Incentive Plan as a material inducement for employment, in compliance with Nasdaq Rule 5635(c)(4). The grants have specific vesting schedules tied to continued employment and stock price.
ORIC awards new hires 44,400 stock options and 7,200 RSUs
ORIC Pharmaceuticals (Nasdaq: ORIC) announced inducement equity grants to three new non-executive employees who started in June 2026. The grants, made on July 1, 2026, include 44,400 non-qualified stock options and 7,200 restricted stock units, approved under Nasdaq Rule 5635(c)(4) as a material inducement for their employment. These awards have multi-year vesting schedules tied to continued service.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are showing bullish sentiment towards several healthcare companies, including Monopar Therapeutics Inc (MNPR), Oric Pharmaceuticals (ORIC), and Tango Therapeutics (TNGX). Analysts from Piper Sandler, Barclays, H.C. Wainwright, and Canaccord Genuity have issued Buy ratings and set price targets, indicating significant upside potential for these stocks. The reports highlight strong consensus ratings and positive outlooks within the Healthcare sector.
Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation
Wedbush has reiterated its "outperform" recommendation for ORIC Pharmaceuticals (ORIC). The article is brief and does not provide further details on the rationale behind this rating.
Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation
Wedbush has reiterated its "outperform" recommendation for ORIC Pharmaceuticals (ORIC). This indicates the firm's continued positive outlook on the company's stock performance.
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC
The article provides a financial overview of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), focusing on its enterprise value to EBITDA forward metric. It details the company's financial data on the TradingView platform, including market performance and other financial indicators. The content is primarily a listing of financial information and navigation within the TradingView interface.
Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ
This article provides the "Price to book forward" value for Oric Pharmaceuticals, Inc. (FWB:4TZ) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The article also lists various financial and community features available on the TradingView platform for this stock.
Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC
This article focuses on the enterprise value to EBIT forward for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It appears to be a financial data point presented on TradingView, indicating a specific financial metric for the company. The content primarily consists of navigation and boilerplate financial service information rather than an in-depth analysis.
Behavioral Patterns of ORIC and Institutional Flows
This article analyzes Oric Pharmaceuticals Inc. (NASDAQ: ORIC), identifying strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for the stock.
Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC)
This article provides key financial data and analyst estimates for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), including current stock price, historical performance, market capitalization, and upcoming earnings dates. It also covers analyst price forecasts, past earnings results, revenue, and net income, offering a comprehensive look at the company's financial health and market sentiment.
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright has reiterated its Buy rating for Oric Pharmaceuticals (ORIC.US) and maintained a target price of $25. This action signals continued confidence in the company's prospects from the analyst firm.
ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay
ORIC Pharmaceuticals' stockholders have approved an amended 2020 Equity Incentive Plan, which revises the annual share increase and clarifies limits on incentive stock options. The company also announced the election of two Class III directors, ratification of KPMG LLP as auditor for 2026, and advisory approval of executive compensation with future votes to be held annually. Shareholder participation in the meeting was high, with 91.36% of outstanding shares represented.
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Oric Pharmaceuticals Inc (ORIC), including its current stock price, market cap, and various technical indicators. It details support and resistance absence, along with buy/sell signals from indicators like MACD, RSI, KDJ, and moving averages. The analysis suggests a "Sell" signal based on a combination of these technical factors.
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $14
Stifel has reiterated its Buy rating for Oric Pharmaceuticals (ORIC.US) and maintained its target price at $14. This indicates a continued positive outlook from the firm regarding Oric Pharmaceuticals' stock performance.
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence
Oric Pharmaceuticals Inc (ORIC) shows a positive institutional confidence score according to TradingKey, with its stock currently trading at $8.630, up 3.85%. The article lists major institutional shareholders including Nextech Invest, LLC, EcoR1 Capital, LLC, and Viking Global Investors LP, detailing their shareholdings and percentage changes.
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Oric Pharmaceuticals Inc (ORIC), highlighting future EPS and revenue growth estimates. Based on 16 analysts, the company has a "Buy" rating with a target price of USD 19.50, representing a significant upside. Recent EPS performance exceeded market expectations, and the next quarter's EPS is also projected.
(ORIC) Movement Within Algorithmic Entry Frameworks
Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is showing strong near-term sentiment despite persistent mid and long-term weakness. An exceptional risk-reward setup targeting a 28.5% gain versus 0.3% risk is identified within an algorithmic entry framework. The article provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels.
(ORIC) Movement Within Algorithmic Entry Frameworks
The article analyzes Oric Pharmaceuticals Inc. (NASDAQ: ORIC), noting a near-term strong sentiment that could challenge current mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 108.5:1 risk-reward setup, targeting a 28.5% gain with minimal risk. The analysis provides specific algorithmic trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
ORIC gains as Stifel resumes at buy on upcoming Pfizer readout
ORIC Pharmaceuticals' stock gained after Stifel resumed coverage with a Buy rating and a $14 price target, citing upcoming Phase 1b data from its CDK2 inhibitor, ORIC-944, partnered with Pfizer. Stifel analysts believe the data, expected by year-end, could be a key catalyst for the stock, particularly given the strong market for CDK2 inhibitors. The firm expects more details on indications in the second half of 2026.
Buy Rating and $14 Target Set for Oric Pharmaceuticals (ORIC)
Stifel analyst Laura Prendergast has reinitiated coverage on Oric Pharmaceuticals (ORIC) with a Buy rating and a $14 price target, ahead of a planned Phase 3 clinical trial for its lead drug candidate, rinzimetostat. The drug targets metastatic castration-resistant prostate cancer, and the trial is significant for the company's future. While ORIC has a low GF Score™ of 35 due to profitability challenges, it boasts strong financial health to support its development pipeline.
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market
ORIC Pharmaceuticals is strategically positioning itself for growth in the expanding oncology market by focusing on therapies that address treatment resistance. The company's pipeline includes rinzimetostat for prostate cancer and enozertinib for non-small cell lung cancer, both targeting mechanisms that differentiate them from existing treatments. With strong analyst support and upcoming clinical milestones, ORIC aims to capitalize on the increasing global demand for innovative cancer therapies.
ORIC: Phase III prostate cancer trial set to start, with strong safety and efficacy data and robust cash runway
ORIC Pharmaceuticals is moving its rinzimetostat drug into a Phase III prostate cancer trial, having finalized the protocol and dosage. The drug has demonstrated competitive efficacy and a superior safety profile compared to rival treatments. Additionally, ORIC's enosertinib EGFR program shows strong CNS activity and safety, with further data expected. The company maintains a strong financial position, with cash reserves projected to last until late 2028.
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
This article provides the transcript from Oric Pharmaceuticals Inc.'s presentation at the Goldman Sachs Healthcare Conference on June 9, 2026. Dominic Piscitelli, CFO of Oric Pharmaceuticals, discusses the recent discontinuation of Fulcrum's PRC2 inhibitor and its potential implications for Oric's Rinzimetostat program in prostate cancer. He notes that while Fulcrum's drug was being studied for sickle cell disease, the mechanism of action overlap is relevant to Oric's work.
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) has granted 34,800 stock options and 5,900 restricted stock units to new non-executive employees hired in May 2026, as inducement grants under their 2022 Equity Incentive Plan. This move comes as analysts like Wedbush and H.C. Wainwright & Co. have reiterated "Buy" and "Outperform" ratings for ORIC, citing positive clinical trial results and a "catalyst-rich" year ahead for its oncology pipeline drugs, Rinzimetostat and Enozertinib. The grants emphasize the company's focus on growth within the expanding oncology treatment sector where innovation is crucial despite rising healthcare costs.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to two new non-executive employees, consisting of 34,800 non-qualified stock options and 5,900 restricted stock units. These grants, approved by ORIC's Compensation Committee, were made under the company's 2022 Inducement Equity Incentive Plan and are subject to vesting schedules tied to continued employment. The move aligns with Nasdaq Rule 5635(c)(4) as a material inducement for employment.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to two new non-executive employees, consisting of 34,800 non-qualified stock options and 5,900 restricted stock units. These grants, approved by ORIC’s Compensation Committee and compliant with Nasdaq Rule 5635(c)(4), are a material inducement to employment and vest over several years depending on the type of grant. ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing treatments for therapeutic resistance in cancer.
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to two new employees under Nasdaq Listing Rule 5635(c)(4). These grants, approved by the Compensation Committee, comprise stock options to purchase 32,500 shares of common stock. The options vest over four years and have an exercise price equal to the closing price of ORIC's common stock on May 28, 2024.
ORIC Pharmaceuticals grants inducement equity to new hires
ORIC Pharmaceuticals granted 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees hired in May 2026. These grants were made on June 1, 2026, as an inducement under Nasdaq Listing Rule 5635(c)(4) and are subject to vesting schedules tied to continued employment. The awards were approved by the Compensation Committee and fall under the company's 2022 Inducement Equity Incentive Plan.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to two new non-executive employees, consisting of 34,800 non-qualified stock options and 5,900 restricted stock units. These grants, approved by ORIC's Compensation Committee and made under the 2022 Inducement Equity Incentive Plan, are a material inducement to employment and are subject to specific vesting schedules.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees hired in May 2026. These grants, made on June 1, 2026, are part of the company's 2022 Inducement Equity Incentive Plan and vest over one to three years, subject to continued employment. The grants were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
Two new ORIC hires receive stock options and RSU awards
ORIC Pharmaceuticals (Nasdaq: ORIC) granted equity awards, comprising 34,800 stock options and 5,900 Restricted Stock Units (RSUs), to two new non-executive employees who started in May 2026. These inducement grants were issued on June 1, 2026, under Nasdaq Rule 5635(c)(4), with multi-year vesting schedules tied to continued employment. Following this announcement, ORIC's stock saw a positive market reaction, gaining 4.53%.
ORIC - ORIC Pharmaceuticals Inc Stock Price and Quote
This article provides comprehensive financial data, stock performance metrics, and a history of analyst ratings for ORIC Pharmaceuticals Inc. It also details recent company news, including inducement grants and presentations at investor conferences, and lists insider trading activities by key executives.
Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15
Goldman Sachs analyst Corinne Johnson has reiterated a Buy rating for Oric Pharmaceuticals (ORIC.US), setting a target price of $15. This assessment is based on TipRanks data, which indicates the analyst has a 49.3% success rate and an average return of 6.2% over the past year. The report emphasizes that investment information is for informational and educational purposes only and does not constitute a recommendation.
This ORIC Pharmaceuticals Insider Increased Their Holding In The Last Year
This article analyzes an insider's share purchase at ORIC Pharmaceuticals. The purchase involved 27,249 shares at an average price of US$10.51, totaling US$286k. This transaction suggests the insider's confidence in the company's future prospects.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced its management will participate in two upcoming investor conferences in June: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. During these events, management will engage in fireside chats and one-on-one meetings, with webcasts of the fireside chats available on the company’s website. ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing treatments to overcome therapeutic resistance in cancer.
Oncology company ORIC plans June talks at Jefferies, Goldman events
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, announced its participation in two investor conferences in June 2026. Management will join fireside chats at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, also holding one-on-one investor meetings. Webcasts of the fireside chats and replays will be available on ORIC’s website.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences in June: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings at both events. Webcasts of the fireside chats will be available on the company's website.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals announced its participation in upcoming investor conferences in June, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings to discuss the company's clinical-stage oncology programs. Webcasts of the fireside chats will be available on their company website.
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock
Cantor Fitzgerald maintained an Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), noting the biotech company's 42% return over the past year and its healthy balance sheet with more cash than debt. The firm highlighted key opinion leaders' positive views on Pfizer's mevrometostat in the MEVPRO-1 trial, which has implications for ORIC, alongside recent developments including a Goldman Sachs upgrade and mixed results for ORIC's rinzimetostat.
Trading Systems Reacting to (ORIC) Volatility
Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is experiencing volatility due to divergent sentiment across different time horizons, indicating choppy market conditions. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to manage risk and optimize positions for institutional traders. The analysis highlights no clear price positioning signal and elevated downside risk.
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), despite the stock appearing overvalued according to InvestingPro analysis, with analysts' price targets ranging from $15 to $25. Key opinion leaders see a 60% probability of success for Pfizer’s mevrometostat in the Phase 3 MEVPRO-1 trial, which holds implications for ORIC, and ORIC itself holds more cash than debt, offering financial flexibility. Recent developments for ORIC include a Goldman Sachs upgrade to Buy, promising clinical data for rinzimetostat, but also trial results for rinzimetostat that matched but did not exceed a competing therapy.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Pomerantz LLP is investigating potential securities fraud claims against ORIC Pharmaceuticals, Inc. on behalf of its investors. This investigation follows a significant 41% drop in ORIC's stock price after a March 31, 2026 press release revealed that its prostate cancer treatment, rinzimetostat, did not meet expectations of being best-in-class among PRC2 blockers. Investors are encouraged to contact the law firm for more information.
ORIC Stock Chart | ORIC PHARMACEUTICALS INC (NASDAQ:ORIC)
This article provides the stock chart and current trading information for ORIC PHARMACEUTICALS INC (NASDAQ:ORIC). It includes the current stock price, after-hours trading data, and navigation to various financial analysis tools and educational resources on ChartMill.com.
T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported
T. Rowe Price Associates, Inc. has reported a 5.4% stake in ORIC Pharmaceuticals, Inc. (ORIC), amounting to 5,387,783 shares of common stock as of March 31, 2026. The filing indicates that T. Rowe Price holds sole voting power over 5,382,293 shares and sole dispositive power over 5,387,783 shares. This disclosure, made via a SCHEDULE 13G form, reveals a significant institutional position, though T. Rowe Price denies beneficial ownership through a written statement.
Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed
Viking Global Investors and affiliated entities have disclosed an 8.26 million share beneficial ownership in Oric Pharmaceuticals Inc., representing 7.8% of the company's common stock as of March 31, 2026. This includes rights to purchase 2.44 million shares through pre-funded warrants. The filing also notes the retirement of David C. Ott as a reporting person.
Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update
Venrock Healthcare affiliates have reported a beneficial ownership of 4.2% in ORIC Pharmaceuticals, Inc., totaling 4,319,765 shares as of March 31, 2026. This stake is held by a group including various Venrock entities and individuals Nimish Shah and Bong Koh, who share voting and dispositive power over the shares. The updated Schedule 13G/A filing indicates a passive investment intent and clarifies the relationships among the reporting persons.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
Pomerantz LLP is investigating potential securities fraud claims against ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). This investigation follows a significant stock price drop after the company announced that its prostate cancer treatment, rinzimetostat, performed similarly to a competitor, failing to meet expectations of being best-in-class. Investors are encouraged to contact Pomerantz LLP to learn more about joining the class action.
[SCHEDULE 13G/A] Oric Pharmaceuticals, Inc. Amended Passive Investment Disclosure
Pfizer Inc. has filed an amended Schedule 13G/A, disclosing a passive investment of 3.3% in ORIC Pharmaceuticals, Inc., totaling 3,442,940 shares. Pfizer, holding sole voting and dispositive power, based this percentage on 103,517,562 outstanding shares of ORIC as of April 27, 2026, as reported in ORIC's Form 10-Q. The filing indicates a neutral sentiment and does not specify plans for future transactions.
